Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

Multiple Sclerosis Clinical Trial

Official title:

Vumerity (Diroximel Fumarate) Prospective MS Pregnancy Exposure Registry

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05658497
• Other study ID #: 272MS401
• Status: Recruiting
• Start date: October 27, 2023
• Est. completion date: July 6, 2032

Study information

• Verified date: May 2024
• Source: Biogen
• Contact: US Biogen Clinical Trial Center
• Phone: 866-633-4636
• Email: clinicaltrials[@]biogen.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The primary objectives of the study are to estimate the risk of major congenital malformations (MCMs) in infants born to women with multiple sclerosis (MS) who were exposed to diroximel fumarate (DRF) at any time from 2 weeks after the first day of their last menstrual period (LMP) up through the first trimester of pregnancy and to comparatively evaluate pregnancy outcomes with MCMs in women with MS who were exposed to DRF at any time from 2 weeks after the first day of their LMP through the first trimester of pregnancy with the following: i) women with MS who were unexposed to disease modifying therapies (DMTs) and, ii) women with MS who were exposed to other DMTs (e.g., Avonex and Tysabri Pregnancy Registries). The secondary objective of the study is to evaluate pregnancy outcomes in women with DRF exposure at any time from 2 weeks after the first day of their LMP through the end of pregnancy compared with the following: i) women with MS who were unexposed to DMTs, ii) women with dimethyl fumarate (DMF) exposure, iii) women with MS who were exposed to other DMTs (e.g., Avonex and Tysabri Pregnancy Registries), and iv) women without MS (e.g., women from external, general population comparators).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 908
• Est. completion date: July 6, 2032
• Est. primary completion date: July 6, 2032
• Accepts healthy volunteers: No
• Gender: Female
• Age group: N/A and older

Eligibility

Key Inclusion Criteria:

• Participant must have a diagnosis of MS
• Documentation that the participant was one of the following:

1. exposed to DRF at any time from 2 weeks after the first day of their LMP (i.e., conception date) up through any time during pregnancy. (If exact exposure dates are unknown, the reporter must be able to specify or estimate trimester of exposure).

2. unexposed to any DMT during pregnancy, defined as having never received DMT therapy; discontinued treatment with DRF at least 1 day before 2 weeks after the first day of their LMP (i.e., conception date); or discontinued a non Registry-specified MS DMT more than 5 times its half-life prior to 2 weeks after the first day of their LMP (i.e., conception date)

• Participants with knowledge of the outcome of the pregnancy (e.g., pregnancy loss or live birth)

Key Exclusion Criteria:

• None NOTE: Other protocol defined Inclusion criteria may apply

Related Conditions & MeSH terms

• Multiple Sclerosis

Intervention

Drug:
• Diroximel Fumarate
Administered as specified in the treatment arm.
• Avonex
Administered as specified in the treatment arm.

Biological:
• Tysabri
Administered as specified in the treatment arm.

Drug:
• Dimethyl Fumarate
Administered as specified in the treatment arm.

Locations

Country	Name	City	State
Germany	Katholisches Klinikum Bochum	Bochum	Nordrhein Westfalen
Ireland	St Vincent's University Hospital	Dublin
Spain	Hospital Universitario Ramon y Cajal	Madrid
United States	IQVIA US Office	Durham	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Biogen

Countries where clinical trial is conducted

United States,  Germany,  Ireland,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Major Congenital Malformations (MCMs)	MCMs include abnormalities in structural development that are medically or cosmetically significant are present at birth, and persist in postnatal life unless or until repaired as evaluated by independent advisors used throughout the registry.	Up to 52 weeks postdelivery
Secondary	Number of Elective or Therapeutic Terminations	Elective or therapeutic pregnancy termination is any induced or voluntary fetal loss during pregnancy. It will be subclassified as elective or therapeutic pregnancy terminations as whether it was due to a fatal anomaly or not.	Up to 9 months of pregnancy
Secondary	Number of Spontaneous Abortions	Spontaneous abortion is defined as any loss of a fetus due to natural causes before 22 weeks of gestation.	Before 22 weeks of gestation
Secondary	Number of Fetal Deaths Including Still Birth	Fetal death or stillbirth refers to the death of a fetus prior to complete expulsion or extraction from its mother at or after 22 weeks of gestation. Death is indicated by the fact that, after such separation, the fetus does not show any evidence of life (e.g., heartbeat, umbilical cord pulsation, or definite movement of voluntary muscles). Fetal death occurring at or after 22 weeks but before 28 weeks of gestation is considered an early fetal loss. Fetal death occurring at or after 28 weeks is considered a late fetal loss.	At or after 22 weeks of gestation
Secondary	Number of Live Births	A live birth refers to a complete expulsion or extraction from its mother of a surviving neonate breathing, or showing any other evidence of life, such as heartbeat, umbilical cord pulsation, or definite movement of voluntary muscles, whether the umbilical cord has been cut or the placenta is attached. Any live birth before 37 weeks of gestation will be considered premature birth. Any live birth at or after 37 weeks but before 42 weeks of gestation will be considered full-term birth. Any live birth at or after 42 weeks of gestation will be considered post-term birth.	Up to delivery (approximately 10 months)
Secondary	Number of Ectopic Pregnancies		Up to 9 months of pregnancy
Secondary	Number of Molar Pregnancies		Up to 9 months of pregnancy
Secondary	Number of Maternal Deaths	Maternal death is death of a pregnant woman during pregnancy, labor, or delivery. Registry will also report maternal deaths that occur up to 12 weeks postdelivery.	Up to 12 weeks postdelivery
Secondary	Number of Neonatal Deaths	Neonatal death is death occurring in a neonate prior to 28 days of life.	Prior to 28 days postdelivery
Secondary	Number of Perinatal Deaths	Perinatal death is death occurring at or after 28 days of life and prior to 12 weeks of life.	At or after 28 days to 12 weeks postdelivery
Secondary	Number of Infant Deaths	Infant death is death occurring between 12 and 52 weeks of life, inclusive.	Between 12 to 52 weeks postdelivery
Secondary	Number of Serious or Opportunistic Infections in Liveborn Children		Up to 52 weeks postdelivery
Secondary	Number of Infants with Abnormal Postnatal Growth and Development	Infant growth measurements will be used to estimate gender-specific weight-for-length, head circumference-for-age, length-for-age, and weight-for-age percentiles. Developmental milestones (i.e., social/emotional, language/communication, neurocognitive, movement/physical development) will be used to determine results of infant status (i.e., below, above, or at age-appropriate achievement).	Up to 52 weeks postdelivery
Secondary	Number of Participants with Pregnancy Complications	Pregnancy complications may include incidences of pre-eclampsia, eclampsia, pregnancy-induced hypertension, preterm labor, gestational diabetes and placenta previa.	Up to 9 months of pregnancy